Fungal infection treatment developer Amplyx Pharmaceuticals had disclosed $142m in funding from investors including Pfizer and Lundbeckfonden Ventures.
Pharmaceutical firm Pfizer has paid an undisclosed amount to purchase portfolio company Amplyx Pharmaceuticals, a US-based developer of anti-infective therapeutics.
Amplyx is developing drugs intended to combat invasive fungal infections. It announced positive topline results for its lead compound, Fosmanogepix (APX001), from phase 2 clinical trials in July 2020.
The purchase comes after Pfizer participated in a series C round for the company also featuring Lundbeckfonden Ventures, the strategic investment arm of pharmaceutical firm Liundbeck, that closed at $91.3m
